Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613832 | 0.91 | RAB9A (0.52) | TUBB1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL6804446 | 0.89 | MAPT (0.57) | MAPTKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL16510468 | 0.86 | MAPT (0.47) | TUBB1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL6803587 | 0.85 | KMT2A (0.45) | TUBB1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL19866164 | 0.85 | MAPT (0.46) | MAPTKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL6612207 | 0.84 | ALDH1A1 (0.60) | KMT2AALDH1A1MEN1SMN1; SMN2HPGD | |
| SCHEMBL14702313 | 0.81 | MAPT (0.46) | MAPTKMT2AALDH1A1MEN1GAA | |
| SCHEMBL16704749 | 0.80 | KMT2A (0.53) | MAPTKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL1849992 | 0.78 | MAPT (0.49) | TUBB1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL6804594 | 0.77 | KMT2A (0.43) | MAPTKMT2AALDH1A1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-01 | — | — | US | disclosed |
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | TERT, TERF2, TERF2IP | TUBB1 558/4885MAPT 1629/4885KMT2A 1256/4885 |
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | TERT, TERF2, TERF2IP | TUBB1 567/4885MAPT 1628/4885KMT2A 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.